Details of the Drug

General Information of Drug (ID: DMCFGP3)

Drug Name
LKA651
Synonyms 45605
Indication
Disease Entry ICD 11 Status REF
Diabetic macular edema 9B71.02 Phase 2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DO0GJ1

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erythropoietin (EPO) TTQG4NR EPO_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Diabetic macular edema
ICD Disease Classification 9B71.02
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Erythropoietin (EPO) DTT EPO 5.72E-01 -0.15 -0.83
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03927690) Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Novartis.